Filtered Products

Gastric cancer ranks as the fifth most prevalent malignancy worldwide and represents the second leading cause of cancer-related mortality. It encompasses multiple histological subtypes, among which gastric adenocarcinoma accounts for over 90% of all cases. The overall prognosis of gastric cancer remains poor. Owing to the absence of characteristic clinical manifestations in the early stage, most patients are diagnosed with incurable advanced disease, thus missing the optimal window for diagnosis and treatment. Organoid technology establishes an innovative technical system for preclinical drug screening in individualized precision therapy. Compared with xenograft models, organoids feature a shorter establishment cycle, straightforward operation, and great convenience for genetic editing modification. Organoid biobanks constructed from large-scale patient samples serve as living human biological repositories, which can support high-throughput drug screening, the formulation of clinical individualized therapeutic strategies, and the research and development of novel anti-tumor agents. In addition to primary tumor tissues, metastatic lesions can also be utilized to generate gastrointestinal tumor organoids; the drug response profiles of such organoids are highly consistent with the clinical therapeutic efficacy observed in corresponding patients.